Caisson Biotech LLC Newsroom - Profile and News Archive
Caisson Biotech, LLC is a collaboration driven biotechnology company specializing in the development of heparosan polymers to improve therapeutic drug delivery and performance. Caisson's HEPtune(r) technology was invented by Chief Scientist and University of Oklahoma Professor Dr. Paul DeAngelis, a world renowned glycobiology and enzyme specialist.
Caisson Biotech is a subsidiary of Heparinex, LLC.
AUSTIN, Texas and OKLAHOMA CITY, Okla., Feb. 23, 2021 (SEND2PRESS NEWSWIRE) — Caisson Biotech and parent company Heparinex are pleased to announce that they have received a positive examination report from the European Patent Office for a patent covering the chemoenzymatic production of heparosan utilized in the HEPtune® drug delivery platform. Once certified, the new patent family will increase patent coverage across Europe, adding to the U.S. holdings.
